NASDAQ:ENLV Enlivex Therapeutics (ENLV) Stock Price, News & Analysis $4.73 +0.09 (+1.94%) Closing price 04:00 PM EasternExtended Trading$4.80 +0.07 (+1.48%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enlivex Therapeutics Stock (NASDAQ:ENLV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Enlivex Therapeutics alerts:Sign Up Key Stats Today's Range$4.49▼$5.0850-Day Range$4.64▼$12.9552-Week Range$4.25▼$31.50Volume60,734 shsAverage Volume62,183 shsMarket Capitalization$79.61 millionP/E RatioN/ADividend YieldN/APrice Target$247.50Consensus RatingHold Company Overview Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings. The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system. Allocetra is currently being evaluated in clinical trials for indications such as sepsis, acute respiratory distress syndrome (ARDS), and cytokine storm associated with COVID-19. Enlivex’s pipeline also explores the potential of macrophage-based treatments to reduce complications in stem cell transplantation and support cancer therapies by mitigating treatment-related hyperinflammation. Enlivex collaborates with academic medical centers and contract research organizations across North America and Europe to advance its clinical programs. The management team brings expertise in immunology, cell therapy manufacturing, and regulatory affairs, positioning the company to scale production and pursue global regulatory approvals. Enlivex continues to build strategic partnerships aimed at broadening access to its cell-based immunotherapies for patients facing severe inflammatory disorders.AI Generated. May Contain Errors. Read More Enlivex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreENLV MarketRank™: Enlivex Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 1367th out of 1,682 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEnlivex Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialEnlivex Therapeutics has a consensus price target of $247.50, representing about 5,132.6% upside from its current price of $4.73.Amount of Analyst CoverageEnlivex Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enlivex Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enlivex Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enlivex Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnlivex Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enlivex Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.73% of the float of Enlivex Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnlivex Therapeutics has a short interest ratio ("days to cover") of 4.02.Change versus previous monthShort interest in Enlivex Therapeutics has recently increased by 336.34%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnlivex Therapeutics does not currently pay a dividend.Dividend GrowthEnlivex Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Enlivex Therapeutics this week, compared to 3 articles on an average week.MarketBeat FollowsOnly 1 people have added Enlivex Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enlivex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.28% of the stock of Enlivex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions1.02% of the stock of Enlivex Therapeutics is held by institutions.Read more about Enlivex Therapeutics' insider trading history. Receive ENLV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENLV Stock News HeadlinesEnlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 BillionJuly 20 at 8:00 AM | globenewswire.comDominari (NASDAQ:DOMH) & Enlivex Therapeutics (NASDAQ:ENLV) Financial ContrastJuly 20 at 2:28 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.July 21 at 1:00 AM | Porter & Company (Ad)Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee OsteoarthritisJuly 13, 2026 | globenewswire.comQ2 EPS Forecast for Enlivex Therapeutics Lifted by AnalystJuly 13, 2026 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Trading Down 8.8% - Time to Sell?July 12, 2026 | americanbankingnews.comEnlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026July 7, 2026 | globenewswire.comEnlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading VolumeJune 24, 2026 | globenewswire.comSee More Headlines ENLV Stock Analysis - Frequently Asked Questions How have ENLV shares performed this year? Enlivex Therapeutics' stock was trading at $10.5480 at the beginning of the year. Since then, ENLV stock has decreased by 55.2% and is now trading at $4.73. How were Enlivex Therapeutics' earnings last quarter? Enlivex Therapeutics Ltd. (NASDAQ:ENLV) released its earnings results on Friday, November, 14th. The company reported ($1.39) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.41. When did Enlivex Therapeutics' stock split? Enlivex Therapeutics's stock reverse split on the morning of Thursday, July 9th 2026.The 1-15 reverse split was announced on Tuesday, July 7th 2026. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 8th 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Enlivex Therapeutics IPO? Enlivex Therapeutics (ENLV) raised $38 million in an initial public offering on Wednesday, July 30th 2014. The company issued 3,200,000 shares at a price of $11.00-$13.00 per share. How do I buy shares of Enlivex Therapeutics? Shares of ENLV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enlivex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enlivex Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), CrowdStrike (CRWD), Adobe (ADBE) and Meta Platforms (META). Company Calendar Last Earnings11/14/2025Today7/21/2026Next Earnings (Estimated)8/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1w+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 For the last 11 days, ENLV's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENLV CIK1596812 Webwww.enlivex.com Phone(728) 662-3301Fax972-2620-8070Employees70Year Founded2012Price Target and Rating Average Price Target for Enlivex Therapeutics$247.50 High Price Target$300.00 Low Price Target$195.00 Potential Upside/Downside+5,132.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($8.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$1.24 billion Net MarginsN/A Pretax MarginN/A Return on Equity248.08% Return on Assets206.39% Debt Debt-to-Equity RatioN/A Current Ratio193.24 Quick Ratio193.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$122.21 per share Price / Book0.04Miscellaneous Outstanding Shares16,830,000Free Float14,765,000Market Cap$79.61 million OptionableOptionable Beta1.52 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ENLV) was last updated on 7/21/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon’s new "tollbooth"The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...Weiss Ratings | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
